Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer
“Neil is a great addition to our Executive Team as we move our programs into later stages of drug development and continue to build Evelo into a fully integrated biotech company. Neil has an exceptional track record and deep experience in leading the development of innovative biologic therapies for inflammatory disease, and in helping to build great biotech companies,” said Simba Gill, Ph.D., chief executive officer of Evelo. “Neil joins our team at an important time in Evelo’s growth, as we advance EDP1815 into Phase 2 development in psoriasis and broader inflammatory disease.”
Prior to Regeneron,
“This is an exciting time to join Evelo’s team, given the completely novel science and therapeutic approach to immune modulation they are pursuing,” said Dr. Graham. “I look forward to working with the team to help realize the potential for these systemically immune modulating microbes in the treatment of inflammatory diseases and cancer.”
About
Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.
Evelo currently has four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contact
jcotrone@evelobio.com
Source: Evelo Biosciences, Inc.